(Hypertension. 1995;26:719.)
© 1995 American Heart Association, Inc.
Articles |
Suppressing Sympathetic Activation in Congestive Heart Failure
A New Therapeutic Strategy
From the Tzanio Hospital, Piraeus, Greece, and the Hypertension and Atherosclerosis Section of the Department of Medicine, Boston (Mass) University School of Medicine.
Correspondence to Haralambos Gavras, MD, Chief, Hypertension and Atherosclerosis Section, Boston University School of Medicine, 80 E Concord St, Boston, MA 02118.
Abstract Neurohormonal activation with increased plasma renin activity and norepinephrine and vasopressin levels is characteristic of congestive heart failure and contributes to further decompensation and poor prognosis. We treated 20 such patients with the centrally acting sympathoinhibitory drug clonidine 0.15 mg BID and obtained hemodynamic measurements by cardiac catheterization and plasma neurohormone levels before and 2 to 3 hours after the first dose; in 7 patients, these measurements were taken again after 1 week of therapy. The initial dose produced significant decreases of 8% in mean arterial pressure, 23% in right atrial pressure, 21% in pulmonary capillary wedge pressure, 19% in mean pulmonary artery pressure, and 12% in heart rate; a 17% increase in stroke volume; and no significant changes in cardiac output and systemic vascular resistance. All changes remained virtually constant after 1 week. Plasma norepinephrine decreased by 28% after the initial dose and 62% after 1 week (P<.01), whereas plasma renin activity remained essentially unchanged. Plasma vasopressin tended to increase, its levels being inversely correlated with those of posttreatment norepinephrine (r=-.48, P<.03). Patients with baseline norepinephrine levels >0.400 ng/mL had significantly poorer baseline hemodynamic parameters and tended to show more improvement with clonidine, although their data remained significantly worse than patients whose baseline norepinephrine was within the normal range. Sympathetic suppression with clonidine in congestive heart failure reduces preload, heart rate, and arterial pressure, all indexes of myocardial energy demand; the lack of significant reduction in systemic vascular resistance and increase in cardiac output might be attributable in part to enhanced release of vasopressin. The data suggest that suppression of activated pressor neurohormones is a rational approach to treatment of congestive heart failure.
Key Words: hormones • norepinephrine • clonidine • heart failure, congestive
This article has been cited by other articles:
 |
|
 |
|
  J. N. Cohn, M. A. Pfeffer, J. Rouleau, N. Sharpe, K. Swedberg, M. Straub, C. Wiltse, T. J. Wright, and for the MOXCON Investigators Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) Eur J Heart Fail, October 1, 2003; 5(5): 659 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Igawa, T. Nozawa, N. Fujii, B.-i. Kato, H. Asanoi, and H. Inoue Long-term treatment with Low-Dose, but not High-Dose, guanethidine improves ventricular function and survival of rats with heart failure after myocardial infarction J. Am. Coll. Cardiol., August 6, 2003; 42(3): 541 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aggarwal, M. D. Esler, M. J. Morris, G. Lambert, and D. M. Kaye Regional Sympathetic Effects of Low-Dose Clonidine in Heart Failure Hypertension, March 1, 2003; 41(3): 553 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Felder, J. Francis, Z.-H. Zhang, S.-G. Wei, R. M. Weiss, and A. K. Johnson Heart failure and the brain: new perspectives Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R259 - R276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brede, F. Wiesmann, R. Jahns, K. Hadamek, C. Arnolt, S. Neubauer, M. J. Lohse, and L. Hein Feedback Inhibition of Catecholamine Release by Two Different {alpha}2-Adrenoceptor Subtypes Prevents Progression of Heart Failure Circulation, November 5, 2002; 106(19): 2491 - 2496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Small, L. E. Wagoner, A. M. Levin, S. L.R. Kardia, and S. B. Liggett Synergistic Polymorphisms of {beta}1- and {alpha}2C-Adrenergic Receptors and the Risk of Congestive Heart Failure N. Engl. J. Med., October 10, 2002; 347(15): 1135 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Roman P-450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function Physiol Rev, January 1, 2002; 82(1): 131 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Grassi, C. Turri, G. Seravalle, G. Bertinieri, A. Pierini, and G. Mancia Effects of Chronic Clonidine Administration on Sympathetic Nerve Traffic and Baroreflex Function in Heart Failure Hypertension, August 1, 2001; 38(2): 286 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aggarwal, M. D. Esler, F. Socratous, and D. M. Kaye Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1246 - 1251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Swedberg, C.-H.a. Bergh, K. Dickstein, J. McNay, M. Steinberg, and Moxonidine Investigators The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure J. Am. Coll. Cardiol., February 1, 2000; 35(2): 398 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gavras, A. J. Manolis, and H. Gavras The Economics of Therapeutic Advances: The Paradigm of Sympathetic Suppression in Chronic Heart Failure Arch Intern Med, December 13, 1999; 159(22): 2634 - 2636. [Full Text] [PDF]
|
|
|
|
|
|
E. R. Azevedo, G. E. Newton, and J. D. Parker Cardiac and systemic sympathetic activity in response to clonidine in human heart failure J. Am. Coll. Cardiol., January 1, 1999; 33(1): 186 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Lang, C. M. Stein, R. A. Nelson, H. B. He, F. J. Belas, I. A. Blair, M. Wood, and A. J. J. Wood Sympathoinhibitory Response to Clonidine Is Blunted in Patients With Heart Failure Hypertension, September 1, 1997; 30(3): 392 - 397. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Manolis, C. Olympios, M. Sifaki, S. Handanis, D. Cokkinos, M. Bresnahan, I. Gavras, and H. Gavras Combined Sympathetic Suppression and Angiotensin-Converting Enzyme Inhibition in Congestive Heart Failure Hypertension, January 1, 1997; 29(1): 525 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Swedberg, M. R. Bristow, J. N. Cohn, H. Dargie, M. Straub, C. Wiltse, T. J. Wright, and for the Moxonidine Safety and Efficacy (MOXSE) Inv Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart Failure Circulation, April 16, 2002; 105(15): 1797 - 1803. [Abstract] [Full Text] [PDF]
|
|